Ever Supreme Bio Technology
- Biotech or pharma, therapeutic R&D
Ever Supreme is a leading company in the field of research and innovation, specializing in immune cell therapy and stem cell new drug development in Taiwan. While current CAR-T therapies are limited to hematologic malignancies and autologous treatments, Ever Supreme's new generation CAR001 therapy offers an off-the-shelf solution that utilizes BiTE-secreting CAR-γδT as a dual targeting strategy for the treatment of solid tumors.
Recently, Ever Supreme's research on CAR.BiTE-γδT immune cell therapy for pre-clinical animal studies was published in the prestigious journal "Advanced Science."
In addition, the US FDA and Taiwan FDA approved Phase I/IIa clinical trial and our clinicaltrial.gov ID # is NCT06150885. Afterwards, we have started enrolling patients in Taiwan, and passed SMC confirming no safety concerns.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}